|
|
|
Nearly one third of Health Advances' business involves M&A due diligence. Health Advances works with both financial and strategic buyers to
assist in understanding the market opportunity for the products or services involved in the deal. Working with hundreds of product companies
and more than 30 private equity firms investing in healthcare deals, Health Advances has established a process and reputation for delivering
high quality insights in short timeframes to meet deal deadlines. This is made possible because of our singular focus on the healthcare industry
and the depth and breadth of our coverage of the industry.
Each year, Health Advances is asked to assist in the due diligence of dozens of deals, including many of the largest deals consummated in the
industry each year. We have been actively involved in over $6 billion of consummated deals in the last three years.
The ability to quickly tap into clinical, scientific and business experts through our proprietary Experts Database, as well as the accumulated and
synthesized work from prior research that is carefully archived to make non-client-proprietary information available for all future projects allows
Health Advances' teams to always get off to a running start and cover more ground more quickly.
Due diligence addresses a wide range of issues, such as:
- Evaluating the upside potential of a product or portfolio of products with changes in sales and marketing strategies and/or tactics.
- Anticipating market dynamics that may result in significant downward pressure on a product's sales in the near future.
- Identifying and quantifying synergies with other products or businesses that may be merged.
|
|
 |
|
|
|
|
|
 learn more
about our work in due diligence for financial and strategic buyers. |
|
|
|
|
 |
|
|
